Differentiated thyroid carcinoma: An update
- PMID: 36002346
- DOI: 10.1016/j.beem.2022.101687
Differentiated thyroid carcinoma: An update
Abstract
Differentiated thyroid carcinoma (DTC) is the most common endocrine cancer. Particularly the incidence of small clinically indolent tumors has been increasing significantly during the last decades because of increased diagnostic scrutiny, while the DTC-related mortality remained unchanged. In light of the increased awareness of the significant risk of detecting clinically indolent tumors and the potential harm and burden associated with overly diagnosis and the treatment, the approach towards management of DTC recently underwent a critical appraisal. The focus lays on reducing the unnecessary burden for patients with very low risk DTC and the correct identification of those who require treatment that is more intensive and/or follow-up. Management of DTC includes a range of different modalities, making multidisciplinary collaboration expedient. In this review, we elaborate on the recent developments in diagnosis, staging and management of DTC with specific focus on the more individualized risk assessment-based approach.
Keywords: diagnosis; differentiated thyroid carcinoma; follicular thyroid carcinoma; papillary thyroid carcinoma; risk stratification; treatment.
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare no conflict of interest.
Similar articles
-
Approach to and treatment of differentiated thyroid carcinoma.Med Clin North Am. 2012 Mar;96(2):369-83. doi: 10.1016/j.mcna.2012.01.002. Epub 2012 Feb 10. Med Clin North Am. 2012. PMID: 22443981 Review.
-
Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy.Thyroid. 2017 Apr;27(4):524-530. doi: 10.1089/thy.2016.0477. Epub 2016 Dec 23. Thyroid. 2017. PMID: 27869547
-
Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons.World J Surg. 2011 Jan;35(1):111-21. doi: 10.1007/s00268-010-0832-6. World J Surg. 2011. PMID: 21042913
-
Risk of recurrence in a homogeneously managed pT3-differentiated thyroid carcinoma population.Langenbecks Arch Surg. 2018 May;403(3):325-332. doi: 10.1007/s00423-018-1657-2. Epub 2018 Feb 14. Langenbecks Arch Surg. 2018. PMID: 29445865
-
Prognostic factors for differentiated thyroid carcinoma and review of the literature.Tumori. 2012 Mar-Apr;98(2):233-7. doi: 10.1177/030089161209800209. Tumori. 2012. PMID: 22677990 Review.
Cited by
-
Probiotic Bacteria Cannot Mitigate the Adverse Effects of Radioactive Iodine-131 Treatment.Cancers (Basel). 2023 Jan 25;15(3):740. doi: 10.3390/cancers15030740. Cancers (Basel). 2023. PMID: 36765697 Free PMC article.
-
Lysicamine Reduces Protein Kinase B (AKT) Activation and Promotes Necrosis in Anaplastic Thyroid Cancer.Pharmaceuticals (Basel). 2023 Dec 4;16(12):1687. doi: 10.3390/ph16121687. Pharmaceuticals (Basel). 2023. PMID: 38139812 Free PMC article.
-
Comparative Analysis of AI-SONICTM Thyroid System and Six Thyroid Risk Stratification Guidelines in Papillary Thyroid Cancer: A Retrospective Cohort Study.Ther Clin Risk Manag. 2024 Aug 23;20:515-528. doi: 10.2147/TCRM.S458576. eCollection 2024. Ther Clin Risk Manag. 2024. PMID: 39193477 Free PMC article.
-
Factors influencing TSH suppression efficacy in postoperative papillary thyroid carcinoma patients: a retrospective cohort study.BMC Surg. 2024 May 3;24(1):133. doi: 10.1186/s12893-024-02426-y. BMC Surg. 2024. PMID: 38702652 Free PMC article.
-
Expression of CLDN1 and EGFR in PTC.Discov Oncol. 2024 Oct 15;15(1):562. doi: 10.1007/s12672-024-01428-9. Discov Oncol. 2024. PMID: 39404969 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
